Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 14/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5859144 | 0.92 | EPHX1 (0.43) | CYP46A1KDM4EALDH1A1LMNAPARP1 | |
| SCHEMBL5859251 | 0.91 | HTT (0.43) | CYP46A1ALDH1A1PARP1 | |
| SCHEMBL5859246 | 0.91 | CYP46A1 (0.49) | CYP46A1KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL5859912 | 0.90 | RAB9A (0.47) | CYP46A1KDM4EALDH1A1GAAHPGD | |
| SCHEMBL5859901 | 0.87 | RAB9A (0.47) | CYP46A1KDM4EALDH1A1GAAHPGD | |
| SCHEMBL6095888 | 0.86 | ALDH1A1 (0.41) | KDM4EALDH1A1PARP1GAA | |
| SCHEMBL6095213 | 0.85 | HSD17B10 (0.42) | KDM4EALDH1A1LMNAGAAHPGD | |
| SCHEMBL5859316 | 0.84 | CYP1A2 (0.42) | KDM4EALDH1A1LMNAGAAHPGD | |
| SCHEMBL5859030 | 0.84 | HTT (0.42) | CYP46A1KDM4EALDH1A1HPGD | |
| SCHEMBL6095332 | 0.84 | KCNH2 (0.43) | KDM4EALDH1A1PARP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122543-B2 | Substituted benzoic acid derivatives having NF-κB inhibiting action | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2006-10-17 | — | — | US | disclosed |
| EP-1437339-A1 | SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-KAPPA B INHIBITING ACTIVITY | Daiichi Suntory Pharma Co., Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-20040039061-A1 | Substituted benzoic acid derivatives exhibiting nf-k b inhibiting activity | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039061-A1 | Substituted benzoic acid derivatives exhibiting nf-k b inhibiting activity | NFKBIA, NFKB2, IKBKB | CYP46A1 709/4885KDM4E 652/4885ALDH1A1 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.